title: Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model.
abstract: In-stent restenosis remains an unresolved problem which occurs in 5-20% of patients undergoing coronary stenting within the first 3-6 months. Neointimal formation is the main contributor to in-stent restenosis. Stent-induced arterial injury and peri-strut inflammation are involved in the process of neointimal formation by activating cytokines and growth factors which induce smooth muscle cell dedifferentiation, migration, and proliferation. Histopathological studies found that neointimal hyperplasia is principally composed of smooth muscle cells, inflammatory cells, and extracellular matrix. Stent-based delivery of anti-proliferative and/or anti-inflammatory agents have shown beneficial effects on neointimal hyperplasia in experimental studies and clinical trials. Tacrolimus (FK506) is a water-insoluble macrolide immunosuppressant discovered in 1984. It has been widely used in reducing the incidence and severity of allograft rejection after organ transplantation. It has also been used to treat other inflammatory conditions such as atopic dermatitis. In this study, we evaluated the efficacy of stent-based delivery of tacrolimus on inflammation and neointimal formation in an overstretched coronary stent model.
authors.affiliation: Department of Cardiology, University of Leuven, U.Z. Gasthuisberg O/N, Herestraat 49, Leuven 3000, Belgium. yanming.huang@med.kuleuven.ac.be
authors.forename: Yanming
authors.initials: Y
authors.lastname: Huang
authors.forename: Koen
authors.initials: K
authors.lastname: Salu
authors.forename: Lan
authors.initials: L
authors.lastname: Wang
authors.forename: Xiaoshun
authors.initials: X
authors.lastname: Liu
authors.forename: Shengqiao
authors.initials: S
authors.lastname: Li
authors.forename: Gunter
authors.initials: G
authors.lastname: Lorenz
authors.forename: Stephan
authors.initials: S
authors.lastname: Wnendt
authors.forename: Eric
authors.initials: E
authors.lastname: Verbeken
authors.forename: Johan
authors.initials: J
authors.lastname: Bosmans
authors.forename: Frans
authors.initials: F
authors.lastname: Van de Werf
authors.forename: Ivan
authors.initials: I
authors.lastname: De Scheerder
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000473:pathology / Q000517:prevention & control*; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D015607:Stents; D013552:Swine; D016559:Tacrolimus / Q000008:administration & dosage*; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D016559:Tacrolimus